SIGA TECHNOLOGIES, INC.

(SIGA)
  Report
Delayed Nasdaq  -  04:00 2022-06-30 pm EDT
11.58 USD   +3.86%
06/24SIGA TECHNOLOGIES, INC.(NASDAQGM : SIGA) dropped from Russell 2000 Growth-Defensive Index
CI
06/24SIGA TECHNOLOGIES, INC.(NASDAQGM : SIGA) dropped from Russell 2000 Defensive Index
CI
06/23TRANSCRIPT : SIGA Technologies, Inc. - Special Call
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)

05/19/2022 | 07:30am EDT

SIGA Technologies, Inc. announced that the U.S. Food and Drug Administration (FDA) approved the intravenous (IV) formulation of TPOXX for the treatment of smallpox. The IV formulation is an important option for those who are unable to swallow the oral capsules of TPOXX. The oral formulation of TPOXX (tecovirimat) is approved in the US, Canada and Europe for the treatment of smallpox. The European approval also includes the treatment of monkeypox, cowpox, and complications from immunization with vaccinia. The IV formulation of TPOXX was cited in the recent U.S. president’s budget request as being used to treat a patient in the U.S. with monkeypox.


© S&P Capital IQ 2022
All news about SIGA TECHNOLOGIES, INC.
06/24SIGA TECHNOLOGIES, INC.(NASDAQGM : SIGA) dropped from Russell 2000 Growth-Defensive Index
CI
06/24SIGA TECHNOLOGIES, INC.(NASDAQGM : SIGA) dropped from Russell 2000 Defensive Index
CI
06/23TRANSCRIPT : SIGA Technologies, Inc. - Special Call
CI
06/23SIGA Technologies Receives Oral TPOXX Orders Totaling $13 Million
MT
06/23Smallpox drugmakers get new orders as monkeypox spreads
RE
06/23Siga Technologies gets orders worth $13 mln for antiviral drug
RE
06/23SIGA Announces $13 Million of International Procurement Orders for Oral TPOXX® (Tecovir..
AQ
06/23SIGA Technologies, Inc. Announces $13 Million of International Procurement Orders for O..
CI
06/22SIGA to Participate in Alliance Global Partners' Monkeypox Panel on Thursday, June 23rd..
AQ
06/21SIGA TECHNOLOGIES, INC.(NASDAQGM : SIGA) added to S&P Pharmaceuticals Select Industry Inde..
CI
More news
Financials (USD)
Sales 2022 125 M - -
Net income 2022 47,8 M - -
Net cash 2022 71,9 M - -
P/E ratio 2022 17,5x
Yield 2022 -
Capitalization 838 M 838 M -
EV / Sales 2022 6,13x
EV / Sales 2023 6,13x
Nbr of Employees 39
Free-Float 55,6%
Chart SIGA TECHNOLOGIES, INC.
Duration : Period :
SIGA Technologies, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SIGA TECHNOLOGIES, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 11,58
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Phillip Louis Gomez Chief Executive Officer
Daniel J. Luckshire Chief Financial Officer & Executive Vice President
Dennis E. Hruby Chief Scientific Officer & Executive VP
Herb Vloedman Chief Information Officer
Tove C. Bolken Senior VP-Operations & Chief Supply Chain Officer
Sector and Competitors
1st jan.Capi. (M$)
SIGA TECHNOLOGIES, INC.48.27%838
JOHNSON & JOHNSON3.46%465 732
ELI LILLY AND COMPANY17.38%290 752
PFIZER, INC.-11.21%285 819
ROCHE HOLDING AG-15.68%273 835
ABBVIE INC.13.12%272 382